All results
14 results for aging well asd
-
DoD Mastectomy
Breast cancer is the most common type of cancer in women. Removal of the breast, called "mastectomy", is performed either when there is cancer-or an increased…
- Ages
- 18 Years - N/A
- Sexes
- All
-
OCEANIC
Researchers are looking for a better way to treat people with atrial fibrillation and prevent stroke or systemic embolism (blood clots travelling through the…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Bleomycin, Carboplatin, Etoposide, or Cisplatin in Pediatric and Adult Patients With Germ Cell Tumor
This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and…
- Ages
- N/A - N/A
- Sexes
- All
-
Takeda TAK-999-3001
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Phase I/II Study of Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patie
Patients with breast cancer are commonly treated with taxane chemotherapy. Some very common side effects of taxanes, such as anemia and peripheral neuropathy,…
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adol
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated…
- Ages
- 6 Months - 21 Years
- Sexes
- All
-
PPMI Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI)
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical…
- Ages
- 30 Years - N/A
- Sexes
- All
-
ACTIV-4d or Novel Experimental COVID Therapies Affecting Host Response (NECTAR)
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients…
- Ages
- 18 Years - N/A
- Sexes
- All
-
TN-31 JAKPOT T1D
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…
- Ages
- 12 Years - 35 Years
- Sexes
- All
-
Testing Triapine w/ Targeted Radiation-based LU177 vs Lu177 alone in pts w/ metastatic NETs
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking…
- Ages
- 18 Years - N/A
- Sexes
- All